Phase 3
N=637
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Multiple Myeloma
Bottom Line
View on ClinicalTrials.gov: NCT00773747 ↗Enrolled (actual)
637
Serious AEs
42.2%
Results posted
Apr 2021
Primary outcome: Primary: Progression-Free Survival (PFS) — 7.63; 6.83 Months — p== 0.0100
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Vorinostat (Drug); bortezomib (Drug); placebo to vorinostat (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Merck Sharp & Dohme LLC
- Primary completion
- Sep 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-Free Survival (PFS) |
7.63; 6.83 | = 0.0100 sig |
| SECONDARY Number of Participants With Grade 3-5 Clinical or Laboratory Adverse Events (AEs) |
272; 240; 108; 85; 11; 17 | — |
| SECONDARY Overall Survival |
1.7; 1.9 | 0.3496 |
| SECONDARY Time to Progression |
7.73; 7.03 | — |
| SECONDARY Objective Response Rate |
56.2; 40.6 | — |
Summary
Study of the efficacy and safety of bortezomib administered in combination with vorinostat in patients with relapsed or refractory multiple myeloma. Histone deacetylases (HDAC) facilitate gene transcription by modulating the uncoiling of chromatin. HDAC function is dysregulated in hematologic and solid malignancies, and this dysregulation may result in over-expression of oncogenes. Thus, inhibition of HDACs may result in anti-cancer effects. HDAC inhibitors, like vorinostat, represent a new class of antitumor agents that have the ability to induce antiproliferative effects including cyto-differentiation, cell cycle growth arrest or apoptosis in various cancer cell lines. Several studies have investigated the in vitro antimyeloma activity of vorinostat in combination with bortezomib and have demonstrated that vorinostat may act synergistically with bortezomib to modulate tumor cell growth. Mitsiades et al have shown that vorinostat enhances the sensitivity of bortezomib. Pei et al found that exposure of human multiple myeloma cell lines & patient-derived multiple myeloma cells to bortezomib and vorinostat resulted in synergistic interactions as a result of: (1) Interruption of NF-kB & related signaling pathways (JNK, XIAP, Mcl-1, etc.) (2) Inhibition of Hsp90 (3)Induction of ER stress signal and (4) acetylation of Dynein/disruption of aggresome function/formation, salvage for ubiquitinated proteins. In addition a marked increase in mitochondrial injury, caspase activation, and apoptosis was also observed. Bortezomib is indicated for the treatment of patients with multiple myeloma. Two Phase I dose-ranging studies of a regimen combining vorinostat and bortezomib among patients with relapsed as well asend-stage, refractory multiple myeloma have been conducted. These studies enrolled a total of 57 patients. In these studies, administration of vorinostat with standard doses of bortezomib resulted in responses in 20/45 (44%) evaluable patients (Weber et al 2007, Badros et al 2007). The purpose of the present study is to definitively evaluate the clinical activity of vorinostat in combination with bortezomib inpatients with multiple myeloma.
Eligibility Criteria
Inclusion criteria
- Participant has an established diagnosis of multiple myeloma based on the myeloma diagnostic criteria.
- Participant has received at least 1 but not more than 3 prior anti-myeloma regimens and has progressive disease after the most recent treatment regimen.
- Participant must have adequate organ function.
Exclusion criteria
- Participant has had a prior allogeneic bone marrow transplant or plans to undergo any type of bone marrow transplantation within 4 weeks of the initiation of study therapy.
- Participant has known hypersensitivity to any components of bortezomib or vorinostat.
- Participant has active Hepatitis B or C, plasma cell leukemia, or is human immunodeficiency virus (HIV) positive.
- Participant has had prior treatment with vorinostat or histone deacetylase (HDAC) inhibitors.
Data sourced from ClinicalTrials.gov (NCT00773747). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.